Frontline treatment for children with osteosarcoma, a type of bone cancer, hasn’t changed in 40 years.
At diagnosis, chemotherapy and surgery are recommended. If a child relapses and the cancer metastasizes to the lungs, where it most often does, the only option is a clinical trial. And for children with metastatic disease, the odds are terrifying: 5-year survival rates drop in half from 60-percent at diagnosis to 30-percent following osteosarcoma relapse.
For these children, the need for safer, effective treatments is urgent.
The story is similar for the 1,700... Read More